Methylphenidate News and Research

RSS

Lannett acquires Kremers Urban Pharmaceuticals from UCB for $1.23 billion

Lannett Company, Inc. today announced that it has completed the acquisition of Kremers Urban Pharmaceuticals Inc., the U.S. specialty generic pharmaceuticals subsidiary of global biopharmaceuticals company UCB S.A.

27 Nov 2015

Researchers encourage more caution in use of ADHD medicine

Authors of new Cochrane Review remain uncertain about effect of widely used medicine on ADHD symptoms, despite large amount of research. Some evidence of increased sleeplessness and loss of appetite leads researchers to encourage more caution in use of methylphenidate.

26 Nov 2015

Stimulant medications for ADHD cause sleep problems among children

Stimulant medications for attention-deficit/hyperactivity disorder (ADHD) cause sleep problems among the children who take them, a new study from the University of Nebraska-Lincoln concludes.

23 Nov 2015

Medication not psychotherapy intensity sways treatment outcome in adult ADHD

Psychological interventions for adult attention deficit/hyperactivity disorder are best combined with methylphenidate, show findings from the COMPAS trial.

9 Nov 2015

Psychoactive drugs can help sedentary people to exercise, suggests Kent endurance expert

Endurance expert suggests drugs could help 'lazy people' exercise In what has been described as 'doping for lazy people' a University of Kent endurance expert has advocated the use of psychoactive drugs to encourage sedentary people to exercise.

4 Nov 2015

Lannett enters into definitive agreement to purchase KU for $1.23 billion

Lannett Company, Inc. today announced that it has signed a definitive agreement to purchase Kremers Urban Pharmaceuticals Inc., the U.S. specialty generic pharmaceuticals subsidiary of global biopharmaceuticals company UCB S.A., for $1.23 billion, plus potential contingency payments.

3 Sep 2015

Ironshore partners with Restore Health to participate in HLD-200 clinical trial to treat ADHD

Ironshore Pharmaceuticals & Development, Inc. has signed an agreement with Restore Health, a company specializing in personalized medicine, to participate in the fulfillment of a double-blind clinical trial, designed to evaluate the safety and efficacy of HLD-200, a new drug in development to treat Attention-deficit/hyperactivity disorder (ADHD).

4 Aug 2015

Aptensio XR once-daily treatment for ADHD to be available in Summer 2015

Today, Rhodes Pharmaceuticals L.P. announced that Aptensio XR, a once-daily central nervous system stimulant indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) will be available to patients beginning Summer 2015.

22 May 2015

Long-term effects of using cognitive-enhancing drugs by healthy people need to be determined

The government, pharmaceutical industry, and national medical organisations need to work together to look at the harms and benefits of long-term use of cognitive-enhancing drugs by healthy individuals, say neuroscientists Professor Barbara Sahakian and Dr Sharon Morein-Zamir from the University of Cambridge in the UK, writing in a Personal View in The Lancet Psychiatry journal.

2 Apr 2015

University of Copenhagen researchers move closer to developing antidote against cocaine addiction

Researchers at the University of Copenhagen have gained new insight into the mechanism behind a protein dopamine transporter that could help in the development of future medical treatment against cocaine addiction.

14 Jan 2015

Psychiatric comorbidities predict bipolar disorder in ADHD children

Children with attention deficit/hyperactivity disorder who also have conduct disorder/oppositional defiant disorder or anxiety disorder are at an increased risk of developing bipolar disorder, research shows.

17 Dec 2014

HLD-200 successfully meets primary endpoint in Phase III study

Highland Therapeutics Inc., a pharmaceutical company, today announced that its wholly owned subsidiary, Ironshore Pharmaceuticals & Development, Inc. has reported positive top-line results from its recently completed Phase III study.

11 Nov 2014

Mice may hold clues in development of ADHD, autism and bipolar disorder

A darting mouse may hold an important clue in the development of Attention Deficit Hyperactivity Disorder (ADHD), autism and bipolar disorder, according to a study by a Vanderbilt University-led research team recently published in the Proceedings of the National Academy of Sciences.

11 Nov 2014

Actavis seeks FDA approval to market generic version of Quillivant XR

Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration seeking approval to market Methylphenidate Hydrochloride for Extended-release Oral Suspension, 5 mg/mL. Actavis' ANDA product is a generic version of Pfizer and Tris Pharma's Quillivant XR®, which is a central nervous system stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder.

16 Oct 2014

Highland completes US$25 million offering of Class A Common Shares

Highland Therapeutics Inc., a pharmaceutical company, today announced it has completed a US$25 million offering of Class A Common Shares. The financing was led by a private equity partner that is committed to Highland's long-term success.

16 Oct 2014

Stimulation therapy and behavioral management training for parents reduce kids’ violent behaviors

Prescribing both a stimulant and an antipsychotic drug to children with physical aggression and attention-deficit/hyperactivity disorder (ADHD), along with teaching parents to use behavior management techniques, reduces aggressive and serious behavioral problems in children, according to a study conducted by researchers in the Department of Psychiatry at Stony Brook University School of Medicine.

4 Sep 2014

Shire, ArmaGen partner to develop AGT-182 drug for treatment of Hunter syndrome

Shire plc, the global specialty biopharmaceutical company, and ArmaGen, a US privately held biotechnology company, today announced a worldwide licensing and collaboration agreement for AGT-182, an investigational enzyme replacement therapy (ERT) for the potential treatment of both the central nervous system (CNS) and somatic manifestations in patients with Hunter syndrome (MPS II).

23 Jul 2014

Stimulating specific brain pathway may induce active emergence from anesthesia

Researchers may be one step closer to better understanding how anesthesia works. A study in the August issue of Anesthesiology, the official medical journal of the American Society of Anesthesiologists- (ASA-), found stimulating a major dopamine-producing region in the brain, the ventral tegmental area (VTA), caused rats to wake from general anesthesia, suggesting that this region plays a key role in restoring consciousness after general anesthesia.

23 Jul 2014

Johnson & Johnson sales increase 9.1% to $19.5 billion in second quarter 2014

Johnson & Johnson today announced sales of $19.5 billion for the second quarter of 2014, an increase of 9.1% as compared to the second quarter of 2013. Operational results increased 9.4% and the negative impact of currency was 0.3%.

15 Jul 2014

Actavis reaches agreement to continue supplying authorized generic version of JPI's Concerta

Actavis plc today announced that it has reached an agreement with Janssen Pharmaceuticals, Inc. to continue supplying the authorized generic version of JPI's Concerta (methylphenidate hydrochloride extended-release tablets).

15 May 2014